Synlogic presents data on synb8802 for enteric hyperoxaluria at american urological association (aua) annual meeting

Cambridge, mass., sept. 10, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on synb8802, an investigational synthetic biotic medicine for the treatment of enteric hyperoxaluria (hox), during the american urological association (aua) annual meeting, being held virtually september 10 – 13th.
SYBX Ratings Summary
SYBX Quant Ranking